MANCHESTERPEPTIDES

Independent research catalogue · COAs and laboratory reports available where supplied

Browse Manchester Peptides

Explore pens, vials, injectables and orals

Explore the collection

Pens & vials

View all products →

Vial · 30 mg

Retatrutide

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways.

£85

Product information

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways. Researchers are studying how this combined signalling may affect appetite, glucose regulation, energy balance and body composition. It is not currently an approved UK medicine.

Evidence and sources at a glance

Human evidence: Randomised phase 2 evidence and reported phase 3 results are available. Check whether a particular result is a peer-reviewed publication or a sponsor announcement, and inspect its population and follow-up.
Regulatory context: Retatrutide is not currently an authorised UK medicine. Investigational status should never be presented as approval.

Phase 2 obesity trial ↗Peer-reviewed randomised human trial indexed by PubMed.
Lilly: current retatrutide programme ↗Sponsor overview, updated September 2026, linking reported phase 3 results and confirming investigational status. Sponsor material should be read alongside the underlying papers.

Read the full evidence map

Related laboratory reports30 mg COA · #172895 30 mg COA · #134840Reports describe the tested samples; batch identity must be matched separately.

Lilly: current retatrutide research programme Read the Retatrutide research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.

View full details

Pen · 40 mg

Retatrutide

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways.

£140

Product information

Evidence and sources at a glance

Human evidence: Randomised phase 2 evidence and reported phase 3 results are available. Check whether a particular result is a peer-reviewed publication or a sponsor announcement, and inspect its population and follow-up.
Regulatory context: Retatrutide is not currently an authorised UK medicine. Investigational status should never be presented as approval.

Phase 2 obesity trial ↗Peer-reviewed randomised human trial indexed by PubMed.
Lilly: current retatrutide programme ↗Sponsor overview, updated September 2026, linking reported phase 3 results and confirming investigational status. Sponsor material should be read alongside the underlying papers.

Read the full evidence map

Related laboratory reports40 mg COA · #195385Reports describe the tested samples; batch identity must be matched separately.

Lilly: current retatrutide research programme Read the Retatrutide research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.

View full details

Pen · 40 mg

Tirzepatide

A dual GIP and GLP-1 receptor agonist associated with appetite, insulin and glucose-regulation pathways.

£140

Product information

A dual GIP and GLP-1 receptor agonist associated with appetite, insulin and glucose-regulation pathways. Authorised prescription versions have established clinical uses, but unlicensed research material is not equivalent to an approved medicine.

Evidence and sources at a glance

Human evidence: Multiple phase 3 trials and real-world use provide a much larger evidence base than is available for most catalogue peptides.
Regulatory context: Authorised tirzepatide medicines have approved indications and controlled supply routes; research material is not equivalent.

NHS tirzepatide overview ↗UK public-health information on authorised use and safety context.
SURMOUNT-1 trial ↗Peer-reviewed randomised human weight-management trial.

Read the full evidence map

NHS: tirzepatide Read the Tirzepatide research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.

View full details

Vial · 100 mg

GHK-Cu

A naturally occurring copper-binding tripeptide researched in skin, extracellular-matrix and wound-repair biology.

£40

Product information

A naturally occurring copper-binding tripeptide researched in skin, extracellular-matrix and wound-repair biology. Studies explore collagen, elastin, tissue remodelling and hair-follicle pathways, with evidence varying by formulation and use.

Evidence and sources at a glance

Human evidence: Some topical and cosmetic studies exist, but formulation quality, scale and endpoints vary.
Regulatory context: Cosmetic ingredient use is not evidence that injectable GHK-Cu is an approved treatment.

Cu-GHK fibroblast study ↗Primary in-vitro study of fibroblast activity and collagen production; formulation and experimental conditions matter.
GHK topical evidence review ↗Recent peer-reviewed review indexed by PubMed.

Read the full evidence map

Related laboratory reports100 mg COA · #220567Reports describe the tested samples; batch identity must be matched separately.

PubMed: topical GHK evidence review Read the GHK-Cu research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.

View full details

Vial set · Wolverine

BPC-157 + TB-500

A catalogue combination of two distinct experimental materials discussed in preclinical tissue-repair research.

£60

Product information

A catalogue combination of two distinct experimental materials discussed in preclinical tissue-repair research. Studies consider cell migration, inflammatory signalling and wound-repair pathways, but the combined ‘Wolverine’ format is not an approved clinical formulation.

Evidence and sources at a glance

Human evidence: Robust, replicated controlled human evidence for BPC-157 is absent, and the marketed blend itself lacks an established clinical evidence base.
Regulatory context: The combined product is not an approved UK medicine and should not be described as a proven injury treatment.

BPC-157 systematic review ↗Peer-reviewed overview of evidence and translational limitations.
PubMed thymosin beta-4 literature ↗Indexed research on thymosin beta-4 biology; not proof of a particular TB-500 product.

Read the full evidence map

PubMed: BPC-157 translational research review Read the BPC-157 + TB-500 research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.

View full details

Vial · 50 mg

MOTS-C

A mitochondria-derived peptide studied as a signal connecting cellular stress, energy use and metabolic adaptation.

£50

Product information

A mitochondria-derived peptide studied as a signal connecting cellular stress, energy use and metabolic adaptation. Research explores mitochondrial function, insulin sensitivity and exercise-response pathways, although most intervention evidence remains preclinical.

Evidence and sources at a glance

Human evidence: Human work includes observational biology and early experimental research, not an established therapeutic evidence base.
Regulatory context: MOTS-C is not an approved medicine for metabolism, exercise performance or ageing.

Original MOTS-C mechanistic study ↗Primary 2015 study using cell and mouse models; it does not establish a treatment effect in humans.
MOTS-C mechanisms review ↗Peer-reviewed review of mitochondrial and metabolic mechanisms.

Read the full evidence map

PubMed: MOTS-c research review Read the MOTS-C research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.

View full details

Built for fast, informed browsing

Everything connected in one research catalogue

Search by name, compare supplied formats, open complete product profiles and move directly between catalogue entries, supporting research guides and available laboratory documentation.

88A–Z catalogue entries

9Reference laboratory reports

3Products compared side by side

Plain-English peptide education

What does each peptide do?

Open clear, expandable guides covering what each catalogue peptide is, why researchers study it and how strong the current evidence is—without dosing advice or exaggerated claims.Explore the complete peptide guide →

Retatrutide Tirzepatide GHK-Cu BPC-157 + TB-500 MOTS-C KPV Epitalon Semax Selank IGF-1 LR3

Independent laboratory documentation

Peptide Certificates of Analysis

View clearly titled COAs for Retatrutide, GHK-Cu, Epitalon, SS-31, NAD+, HGH and BPC-157 with TB-500, including measured results and verification references.View all certificates →

Manchester Peptides research information

Manchester Peptides is a UK research-reference catalogue covering peptide names, supplied formats, certificates of analysis and plain-English educational material. Learn how to interpret laboratory reports, understand peptide terminology and distinguish experimental findings from established clinical evidence.

Explore the research guides →

Research reference centre

Peptide catalogue, COAs and evidence guides

Find the right reference

Search by compound name or a familiar abbreviation, then check its listed strength and presentation. Product profiles connect the catalogue entry with the relevant research guide.

Open the A–Z catalogue

Check laboratory documents

Review available third-party reports by product, labelled strength, task number, measured result and verification key. Each certificate applies only to the sample identified on it.

Browse certificates of analysis

Understand the science

Read accessible guides to peptide research, HPLC, LC–MS, purity, clinical-trial phases and the difference between preclinical findings and human evidence.

Read the research guides